$MEDI Ketamine is a drug that has been approved for use in the US since 1970
Because of this long history of Ketamine research, its long-term effects are known. This means that its risks can be more anticipated and mitigated in comparison to other psychedelics.
KetamineOne Capital Limited ( $MEDI.NE , $KONEF) has a network of 16 Ketamine therapy clinics located in Canada and the U.S.
They have been operating in the Ketamine sector for over 23 years
Currently they are selling at $1.30 CAD with a MC of 154.72M
Recently, $MEDI acquired KGK Science Inc. to be their contract research division.
KGK recently applied for a Canadian controlled drugs and substances dealer’s licence.
If approved by Health Canada, the licence will authorize KGK to act as a centralized distributor for large, multi-location clinical ketamine trials.
You can read more here: https://financialpost.com/globe-newswire/ketamine-one-advances-research-capabilities-via-controlled-substance-dealers-licence-application-the-company-and-its-subsidiary-kgk-science-have-also-completed-the-pre-qualification-audits-of-its-cana